Search Result
Results for "
anti-malarial agent
" in MedChemExpress (MCE) Product Catalog:
17
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-114197
-
-
-
- HY-W009109
-
-
-
- HY-149938
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 25 is an orally active 1,4-naphthoquinones derivative with antimalarial activity. Antimalarial agent 25 shows cytotoxicity against P. falciparum. Antimalarial agent 25 inhibits P. burghei induced parasitemia in vivo .
|
-
-
- HY-148429
-
|
|
Parasite
|
Others
|
|
Antimalarial agent 17 is an antimalarial agent, also acts as a herbicide. Antimalarial agent 17 is photosystem II inhibitor, shows post-emergence herbicidal activity equal to commercial herbicides .
|
-
-
- HY-149937
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 24 (Compound 7) is an antimalarial agent in vitro. Antimalarial agent 24 inhibits P. falciparum W2 strain with an IC50 of 0.81 μM. Antimalarial agent 24 displays a CC50 higher than 200 μM against HepG2 cells .
|
-
-
- HY-161170
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 36 (compound 1) is an antimalarial agent, with the EC50s of 58 nM and 42 nM, for Dd2 and 3D7, respectively. Antimalarial agent 36 targets EphA2 .
|
-
-
- HY-115905
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 9 (Compound 11) is a potent antimalarial agent. Antimalarial agent 9 is a quinoline-imidazole derivative compound. Antimalarial agent 9 exhibits significant antimalarial efficacy in-vitro against both CQ-sensitive (IC50-0.14 μM) and MDR strain (IC50-0.41 μM) with minimal cytotoxicity and high selectivity .
|
-
-
- HY-152614
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 19 (compound 6e) is an antimalarial active agent. Antimalarial agent 19 has antimalarial activity for the blood stage of P. falciparum K1 and P. berghei with EC50 values of 0.3 µM, 15.3 µM, respectively. Antimalarial agent 19 has good aqueous solubility, intestinal permeability and microsomal stability compared to gamhepathiopine .
|
-
-
- HY-149939
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 26 is an orally active 1,4-naphthoquinones derivative with antimalarial activities. Antimalarial agent 26 shows cytotoxicity against P. falciparum and selectivity over mammalian cell lines. Antimalarial agent 26 inhibits P. burghei induced parasitemia in vivo .
|
-
-
- HY-147198
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 13 (Compound 1) is a potent antimalarial agent. Antimalarial agent 13 shows inhibition with EC50 values of 124 nM and 2.5 μM against P. falciparum parasite and HepG2, respectively .
|
-
-
- HY-149919
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 23 is an antimalarial benzimidazole with IC50s of 0.08 μM and 0.10 μM for PfNF54 and PfK1, respectively. Antimalarial agent 23 has potent β-hematin inhibition activity. Antimalarial agent 23 does not directly inhibit the conversion of heme to hemozoin .
|
-
-
- HY-151965
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 18 is an potent antimalarial agent, based on electronic, highly lipophilic and siderophoric properties. Antimalarial agent 18 belongs to acyloxymethyl series, as a fosmidomycin surrogate, which is potent IspC inhibitor against the non-mevalonate isoprenoid biosynthesis pathway. Antimalarial agent 18 inhibits P. falciparum (IC50=50 nM) and A. baumanii (IC50=390 nM) .
|
-
-
- HY-150066
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
Antimalarial agent 16 (Compound 4h) is a parasite inhibitor. Antimalarial agent 16 shows antimalarial activity, and can inhibit P. falciparum parasite growth (IC50=2.0 nM) .
|
-
-
- HY-163070
-
|
|
Others
|
Infection
|
|
Antimalarial agent 35 (compound QP11) is a selective inhibitor FP2. Antimalarial agent 35 has antimalarial activity and shows synergistic effects when combined with chloroquine(HY-17589A) .
|
-
-
- HY-143487
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 12 (compound R-3b) is a potent antimalarial agent. Antimalarial agent 12 shows growth inhibition on P. falciparum Dd2 Strain (EC50=155 nM), 3D7 strain (EC50=136 nM). Antimalarial agent 12 has CC50 values of 10,000 to 50,000 nM for HEK-293 and hPHep cell lines. Antimalarial agent 12 has a MIC of >250,000 nM for Escherichia coli .
|
-
-
- HY-145704
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 8 (Compound 7e) is a novel orally active class of antimalarials. Antimalarial agent 8 is potent in vitro against P. falciparum and is orally efficacious (40 mg/kg) in an in vivo mouse model of malaria .
|
-
-
- HY-150065
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
Antimalarial agent 15 (Compound 4e) is a parasite inhibitor. Antimalarial agent 15 shows antimalarial activity, and can inhibit P. falciparum 3D7 parasite growth (IC50=20 nM) .
|
-
-
- HY-146769
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 11 (compound 1), a spirocyclic chromane, is a potent antimalarial agent. Antimalarial agent 11 exhibits excellent potency with an EC50 of 350 nM against the Chloroquine-resistant Dd2 strain. Antimalarial agent 11 has EC50s of 1.48 µM and 1.81 µM against D6 and ARC08-022 strains, respectively .
|
-
-
- HY-155689
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 30 (compound 11) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC50 of 5.2 μM .
|
-
-
- HY-155688
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 29 (compound 16) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC50 of 5.2 μM .
|
-
-
- HY-115721
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 2 is a novel orally efficacious antimalarials that suggests a fast in vitro killing profile.
|
-
-
- HY-143409
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 10 (Compound 17b) is an aminoalcohol quinoline compound. Antimalarial agent 10 is an antimalarial agent with IC50 values of 14.9 nM and 11.0 nM against respectively Pf3D7 and PfW2 and a selectivity index higher than 770 whatever the cell line is .
|
-
-
- HY-123915
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 20 (Compound 49c) is an antimalarial agent with an IC50 of 0.6 nM against P. falciparum NF54 parasite strain in the NF54 albumax assay .
|
-
-
- HY-149882
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 27 (compound 11a) is an antimalarial agent, potently targeting to P.falciparum (IC50=0.37 μM). Antimalarial agent 27 acts function via P.falciparum DXR (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibition (IC50=0.11 μM) .
|
-
-
- HY-145327
-
|
|
Na+/K+ ATPase
Parasite
|
Infection
|
|
Antimalarial agent 7 is a potent inhibitor of PfATP4. PfATP4 is an essential ion pump on the parasite surface. Antimalarial agent 7 has the potential for the research of human malaria parasite, Plasmodium falciparum .
|
-
-
- HY-155354
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 33 (compound 5g) has antiplasmodial activity against erythrocytic and hepatic stages of Plasmodium with an EC50 of 1.1 μM for K1 P. falciparum strain. Antimalarial agent 33 demonstrats enhanced microsomal stability (T1/2=29 min). Antimalarial agent 33 has no significant cytotoxicity against primary hepatocytes .
|
-
-
- HY-161171
-
|
|
Parasite
Ephrin Receptor
|
Cancer
|
|
Antimalarial agent 37 (compound 33) is a selective inhibitor against Type Ⅱ kinase with antiplasmodial activity. Antimalarial agent 37 exhibited cytotoxicity and selectivity towards cancer cells HepG2 and MCF 7 .
|
-
-
- HY-155536
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 28 (Compound 2i) is an antiplasmodial agent. Antimalarial agent 28 inhibits P. berghei, with IC50s of 0.561 μM, 0.14 μM, 4.34 μM for Liver stage, early gametocytes and ring stages of P. falciparum .
|
-
-
- HY-155130
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 31 (compound 7k) is an orally active Plasmodium falciparum aspartic protease plasmepsin X (PMX) inhibitor .
|
-
-
- HY-163063
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC50 = 0.16 μM) .
|
-
-
- HY-132906
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 3 shows nanomolar antiplasmodial activity (IC50 = 0.035 μM) and has a very high selectivity index with respect to mammalian cells.
|
-
-
- HY-147850
-
|
|
Parasite
|
Infection
|
|
JMI-346 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-346 inhibits the growth of CQ S (3D7; IC50=13 µM) and CQ R (RKL-9; IC50=33 µM) strains of P. falciparum. JMI-346 has the potential to be used as an anti-malarial agent .
|
-
-
- HY-111529
-
|
WR 238605
|
Parasite
|
Infection
|
|
Tafenoquine (WR 238605) is an 8-aminoquinoline. Tafenoquine is an anti-malarial prophylactic agent .
|
-
-
- HY-111529A
-
|
WR 238605 (Succinate)
|
Parasite
|
Infection
|
|
Tafenoquine Succinate (WR 238605 Succinate) is an 8-aminoquinoline. Tafenoquine is an anti-malarial prophylactic agent .
|
-
-
- HY-147849
-
|
|
Parasite
|
Infection
|
|
JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ S (3D7; IC50=8.8 µM) and CQ R (RKL-9; IC50=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .
|
-
-
- HY-149961
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
Anti-inflammatory agent 40 is a potential and orally active anti-malarial and anti-inflammatory agent. Anti-inflammatory agent 40 inhibits carrageenan induced paw swelling in vivo.
|
-
-
- HY-14749
-
|
|
Parasite
|
Infection
|
|
Pyronaridine is an orally active Mannich base anti-malarial agent. Pyronaridine is active against P. falciparum and Echinococcus granulosus infection .
|
-
-
- HY-14749A
-
|
|
Parasite
|
Infection
|
|
Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection .
|
-
-
- HY-156843
-
|
|
Others
|
Cancer
|
|
Antiproliferative agent-38 (com 18) is a tetracyclic ring, but its most reactive ring nitrogen (probably the quinoline moiety) cannot undergo N-alkylation. Antiproliferative agent-38 lacks anti-malarial activity and lacks anti-cancer cell proliferation activity .
|
-
-
- HY-14749AS
-
|
|
Parasite
|
Infection
|
|
Pyronaridine-d4 (tetraphosphate) is the deuterium labeled Pyronaridine tetraphosphate[1]. Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection[2][3].
|
-
-
- HY-B0094
-
|
Qinghaosu; NSC 369397
|
HCV
Parasite
Akt
Ferroptosis
|
Infection
Neurological Disease
Cancer
|
|
Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants . Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects .
|
-
-
- HY-B0094S
-
|
Qinghaosu-d3; NSC 369397-d3
|
Akt
Ferroptosis
HCV
Parasite
|
Infection
Neurological Disease
Cancer
|
|
Artemisinin-d3 is the deuterium labeled Artemisinin. Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].
|
-
-
- HY-153612
-
|
|
GLUT
Parasite
|
Infection
Inflammation/Immunology
|
|
MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
|
-
-
- HY-B1896A
-
|
|
Parasite
|
Infection
|
|
Piperaquine phosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin .
|
-
-
- HY-B1896
-
|
|
Parasite
|
Infection
|
|
Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin .
|
-
-
- HY-B1896B
-
|
|
Parasite
|
Infection
|
|
Piperaquine tetraphosphate tetrahydrate is a bisquinoline antimalarial agent. Piperaquine tetraphosphate tetrahydrate can be used in antimalarial research in combination with Artemisinin .
|
-
-
- HY-N4106
-
|
Dihydroqinghao acid
|
Parasite
Ferroptosis
|
Infection
|
|
Dihydroartemisinic acid (Dihydroqinghao acid) is a biosynthetic precursor to the antimalarial agent Artemisinin .
|
-
-
- HY-B1896S
-
|
|
Parasite
|
Infection
|
|
Piperaquine-d6 is the deuterium labeled Piperaquine[1]. Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin[2][3].
|
-
-
- HY-B0803S
-
-
-
- HY-A0130
-
|
Sulfametopyrazine; AS-18908
|
Parasite
Bacterial
Antibiotic
|
Infection
|
|
Sulfalene (Sulfametopyrazine) is an antimalarial agent. Sulfalene is also a long-acting sulfonamide antibacterial.
|
-
- HY-118865S
-
|
|
Isotope-Labeled Compounds
Parasite
|
Infection
|
|
Piperaquine-d6 (tetraphosphate) is the deuterium labeled Piperaquine tetraphosphate. Piperaquine tetraphosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin[1][2].
|
-
- HY-N3957
-
|
|
Parasite
|
Infection
|
|
1-(26-Hydroxyhexacosanoyl)-glycerol is a potent antimalarial agent. 1-(26-Hydroxyhexacosanoyl)-glycerol shows antimalarial activity with an IC50 value of 9.48 µM for Plasmodium falciparum .
|
-
- HY-B0806S
-
|
|
Parasite
|
Infection
|
|
Proguanil-d6 is the deuterium labeled Proguanil, which is a prophylactic antimalarial agent.
|
-
- HY-N0352
-
|
|
Parasite
|
Infection
|
|
Tuberostemonine, an alkaloid, is an antimalarial agent that targets Plasmodium falciparum ferredoxin-NADP + reductases (pfFNR) .
|
-
- HY-100358
-
|
|
Parasite
|
Infection
|
|
AQ-13 dihydrochloride is an aminoquinoline antimalarial agent that is effective against drug-resistant strains of Plasmodium falciparum.
|
-
- HY-112853
-
|
FR-31564
|
Bacterial
Antibiotic
|
Infection
|
|
Fosmidomycin sodium salt is a phosphonic acid antibiotic and a antimalarial agent, which is active against both Gram-negative and Gram-positive bacteria.
|
-
- HY-10852
-
|
OZ 277; RBx 11160
|
Parasite
|
Infection
|
|
Arterolane is an antimalarial agent, with IC50 of both 1.1 nM against P. falciparum Ro73 and W2, respectively.
|
-
- HY-100662
-
|
Bisdesethylchloroquine
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Didesethyl chloroquine (Bisdesethylchloroquine) is a major metabolite of the antimalarial agent Chloroquine. Didesethyl chloroquine is a potent myocardial depressant .
|
-
- HY-157794
-
|
|
Parasite
|
Infection
|
|
6-Nitroquinazoline is an antimalarial agent. 6-Nitroquinazoline is also a substrate for human liver aldehyde oxidase .
|
-
- HY-13833
-
|
|
Parasite
|
Infection
|
|
Endochin is an antimalarial agent. Endochin inhibits T.gondii with an IC50 of 0.003 nM. Endochin is also active against experimental toxoplasmosis .
|
-
- HY-19364
-
|
Ferrochloroquine; SSR97193
|
Parasite
|
Infection
|
|
Ferroquine (Ferrochloroquine), a ferrocenyl analogue of Chloroquine, is an antimalarial agent. Ferroquine shows parasiticidal effect on Plasmodium by inducing oxidative stress and the subsequent destruction of the membrane .
|
-
- HY-161384
-
|
|
Parasite
|
Infection
|
|
WJM-715 is an antimalarial agent with an EC50 of 0.015 μM by trageting STAR-related lipid transfer protein (PfSTART1) with a KD of 14 nM .
|
-
- HY-111746
-
|
|
Parasite
|
Infection
|
|
CWHM-1008 is a potent and orally active antimalarial agent, with EC50 values of 46 and 21 nM against agent-sensitive Plasmodium falciparum 3D7 and drug-resistant Dd2 strains, respectively .
|
-
- HY-N9438
-
-
- HY-17036
-
|
|
Parasite
|
Infection
|
|
Naphthoquine phosphate is a potent and orally active antimalarial agent. Naphthoquine phosphate has thorough killing function for various schizonts of plasmodia, including resistance of P. falciparum to Chloroquine .
|
-
- HY-136448
-
|
|
Parasite
|
Infection
|
|
SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent. SJ000025081 results in an obvious suppression of the parasitemia in a murine malaria model infected with P. yoelii .
|
-
- HY-A0130S
-
-
- HY-145964
-
|
|
Parasite
|
Infection
|
|
INE963 is a potent and fast-acting blood-stage antimalarial agent, with an EC50s of 3-6 nM. INE963 is potential for single-dose cures in uncomplicated malaria .
|
-
- HY-135578
-
|
|
Parasite
|
Infection
|
|
Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .
|
-
- HY-13735B
-
|
Mepacrine hydrochloride hydrate; SN-390 hydrochloride hydrate
|
Parasite
Apoptosis
Autophagy
Mitophagy
|
Infection
Cancer
|
|
Quinacrine hydrochloride hydrate (Mepacrine hydrochloride hydrate) is an antimalarial agent, which possess anticancer effect both in vitro and vivo. Quinacrine hydrochloride hydrate suppresses NF-κB and activates p53 signaling, which results in the induction of the apoptosis .
|
-
- HY-139672
-
|
|
Parasite
|
Infection
|
|
BRD5018 is an antimalarial agent. BRD5018 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-148177
-
|
ZY-19489; MMV 253; AZ13721412
|
Parasite
|
Infection
|
|
Sutidiazine (ZY-19489) is an orally active and antimalarial agent. Sutidiazine inhibits parasitemia-induced infection. Sutidiazine shows short half-lives (approximately 7 h) and an exposure effect .
|
-
- HY-100662S
-
|
Bisdesethylchloroquine-d4
|
Isotope-Labeled Compounds
Drug Metabolite
|
Cardiovascular Disease
|
|
Didesethyl chloroquine-d4 is the deuterium labeled Didesethyl chloroquine. Didesethyl chloroquine (Bisdesethylchloroquine) is a major metabolite of the antimalarial agent Chloroquine. Didesethyl chloroquine is a potent myocardial depressant[1][2].
|
-
- HY-13735A
-
|
Mepacrine dihydrochloride; SN-390 dihydrochloride
|
Parasite
Apoptosis
Autophagy
Mitophagy
|
Infection
Cancer
|
|
Quinacrine (Mepacrine) dihydrochloride is an orally bioavailable antimalarial agent, which possess anticancer effect both in vitro and vivo. Quinacrine dihydrochloride suppresses NF-κB and activate p53 signaling, which results in the induction of the apoptosis .
|
-
- HY-W078844
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria .
|
-
- HY-100711A
-
|
Prodigiosine hydrochloride
|
Bacterial
Apoptosis
Fungal
Wnt
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Prodigiosin (Prodigiosine) hydrochloride is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin hydrochloride is a potent proapoptotic agent, and inhibits Wnt/β-catenin pathway. Prodigiosin hydrochloride has antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive, and anticancer properties .
|
-
- HY-W112166A
-
|
|
Bacterial
|
Infection
|
|
4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-13836
-
|
|
Parasite
|
Infection
|
|
ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial .
|
-
- HY-18062
-
|
Pirimecidan; Pirimetamin; RP 4753
|
Antifolate
Parasite
|
Infection
|
|
Pyrimethamine (Pirimecidan) is a potent, orally active dihydrofolate reductase (DHFR) inhibitor. Pyrimethamine is an antimalarial agent. Pyrimethamine affects the nucleoprotein metabolism of malarial parasites by interference in the folic–folinic acid systems and affects cell division by inhibiting the conversion of dihydrofolate to tetrahydrofolate .
|
-
- HY-108640A
-
|
|
MDM-2/p53
Parasite
Apoptosis
|
Infection
Cancer
|
|
HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents . Antimalarial activity .
|
-
- HY-108640
-
|
|
MDM-2/p53
Parasite
Apoptosis
|
Infection
Cancer
|
|
HLI373 is an efficacious Hdm2 inhibitor. HLI373 inhibits the ubiquitin ligase activity of Hdm2. HLI373 is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents . Antimalarial activity .
|
-
- HY-152313
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Bromoadenosine, antimalarial agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106866
-
|
CDRI 80/53; Elubaquine
|
Parasite
|
Infection
|
|
Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A). Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria .
|
-
- HY-B1370A
-
|
(S)-HCQ
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
|
|
(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine . Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro .
|
-
- HY-155846
-
|
|
Parasite
Bacterial
|
Infection
|
|
Antileishmanial agent-22 (compound 15b) is a parasite inhibitor and an antibacterial agent, with antileishmanial, antimalarial, and anti-tubercular activities. Antileishmanial agent-22 inhibits leishmanial (IC50=0.408 μM) based on antifolate mechanism. And, Antileishmanial agent-22 inhibits Folic acid and Folinic acid at 100 μM with inhibitory rates of 88% and 94%, respectively. Antileishmanial agent-22 inhibits P. berghei in vivo and in vitro, with 96.67% suppression under 48.4 μM/kg/day and 0.038 μM (IC50), respectively. Moreover, Antileishmanial agent-22 inhibits M. tuberculosis with MIC of 28.44 μM .
|
-
- HY-B1370
-
-
- HY-B1370B
-
|
(R)-HCQ
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
|
|
(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .
|
-
- HY-W026467
-
|
|
Parasite
|
Infection
|
|
MMV665916, a quinazolinedione derivative, is an antimalarial agent. MMV665916 displays antiplasmodial activity against P. falciparum FcB1 strain with EC50 value of 0.4 µM and presents the high selectivity index (SI>250) .
|
-
- HY-131262
-
|
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol
|
SARS-CoV
Toll-like Receptor (TLR)
|
Others
|
|
Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .
|
-
- HY-131263
-
|
|
Drug Metabolite
|
Others
|
|
Hydroxychloroquine Impurity F is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .
|
-
- HY-108024A
-
|
KAF156 hydrochloride; GNF156 hydrochloride
|
Parasite
|
Infection
|
|
Ganaplacide (KAF156) hydrochloride is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide hydrochloride is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide hydrochloride is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .
|
-
- HY-13735
-
-
- HY-108024
-
|
KAF156; GNF156
|
Parasite
|
Infection
|
|
Ganaplacide (KAF156) is a first-in-class,
orally active imidazolopiperazine antimalarial agent.
Ganaplacide is active against a broad range of Plasmodium
species, including drug-resistant parasites. Ganaplacide is parasiticidal
against both asexual and sexual blood stages as well as the liver stages of the
parasite .
|
-
- HY-17437A
-
-
- HY-123561
-
|
|
Parasite
|
Infection
|
|
MMV008138 is a species-selective IspD (enzyme 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase)-targeting antimalarial agent, with an IC50 of 44 nM for PfIspD (P. falciparum IspD). MMV008138 inhibits the growth of P. falciparum Dd2 strain with an IC50 of 250 nM .
|
-
- HY-117684
-
|
DDD107498; DDD-498; M5717
|
Parasite
CaMK
|
Infection
|
|
Cabamiquine (DDD107498) is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. Cabamiquine inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2 .
|
-
- HY-17589
-
-
- HY-W031727S
-
-
- HY-117684A
-
|
DDD107498 succinate; DDD-498 succinate; M5717 succinate
|
Parasite
CaMK
|
Infection
|
|
Cabamiquine (DDD107498) succinate is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. Cabamiquine succinate inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2 .
|
-
- HY-17589A
-
-
- HY-17589B
-
-
- HY-B1322A
-
-
- HY-17437
-
-
- HY-W031727S1
-
|
|
Autophagy
SARS-CoV
Toll-like Receptor (TLR)
Parasite
|
|
|
Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
|
-
- HY-W795264
-
|
|
Parasite
|
Infection
|
|
FR900098 is an antimalarial agent that inhibits 1-deoxy-d-xylulose-5-phosphate (DXP) reductoisomerase. FR900098 has no significant acute toxicity or genotoxicity, and does not have the ability to cause chromosome breakage or heterogeneity. FR900098 has no effect on bone marrow red blood cells in NMRI mice .
|
-
- HY-16438
-
|
|
Apoptosis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
|
-
- HY-108251
-
|
DAMPA
|
Antifolate
Drug Metabolite
Dihydrofolate reductase (DHFR)
Parasite
|
Infection
Inflammation/Immunology
|
|
Methotrexate metabolite (DAMPA), the active metabolite of Methotrexate. Methotrexate is a folic acid antagonist that is widely used as an immunosuppressant and chemotherapeutic agent . Methotrexate metabolite is an antimalarial agent, which inhibits the parasite growth with an IC50 of 446 nM against the antifolate-sensitive strain and 812 nM against the highly resistant strain under physiological folate conditions. Methotrexate metabolite is inactive against mammalian cells. Methotrexate metabolite is a minimal inhibitor of dihydrofolate reductase among metabolites of methotrexate .
|
-
- HY-B1322
-
-
- HY-B1322B
-
|
Amodiaquin dihydrochloride
|
|
|
|
Amodiaquine dihydrochloride (Amodiaquin dihydrochloride), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor with a Ki of 18.6 nM. Amodiaquine dihydrochloride is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect .
|
-
- HY-122817
-
|
|
Antibiotic
Parasite
|
Infection
|
|
FR900098 sodium is an antimalarial agent that inhibits 1-deoxy-d-xylulose-5-phosphate (DXP) reductoisomerase. FR900098 sodium has no significant acute toxicity or genotoxicity, and does not have the ability to cause chromosome breakage or heterogeneity. FR900098 sodium has no effect on bone marrow red blood cells in NMRI mice .
|
-
- HY-B1370S
-
|
HCQ-d4 (sulfate)
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
Cancer
|
|
Hydroxychloroquine-d4 (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
- HY-Y0152A
-
|
(8R,9S)-Cinchonine monohydrochloride hydrate; LA40221 monohydrochloride hydrate
|
Parasite
Apoptosis
|
Infection
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Cinchonine ((8R,9S)-Cinchonine) monohydrochloride hydrate is a natural compound which has been effectively used as antimalarial agent. Cinchonine monohydrochloride hydrate activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. Cinchonine monohydrochloride hydrate is also an inhibitor of human platelet aggregation. Cinchonine monohydrochloride hydrate possesses a suppressive effect on adipogenesis .
|
-
- HY-13832
-
|
Atavaquone
|
Parasite
Cytochrome P450
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia .
|
-
- HY-B1370R
-
|
HCQ sulfate (Standard)
|
Parasite
Toll-like Receptor (TLR)
SARS-CoV
Autophagy
|
Infection
Cancer
|
|
Hydroxychloroquine (sulfate) (Standard) is the analytical standard of Hydroxychloroquine (sulfate). This product is intended for research and analytical applications. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro .
|
-
- HY-156028
-
|
|
Parasite
|
Infection
|
|
FIKK9.1-IN-1 (Compound 1) is a FIKK9.1 inhibitor. FIKK9.1-IN-1 interacts with the ATP?binding residues in FIKK9.1. FIKK9.1-IN-1 is an antimalarial agent (IC50: 2.68 μg/mL) and disrupts the parasite life cycle and leads to the death of parasites .
|
-
- HY-B1322AS
-
|
|
Parasite
Histone Methyltransferase
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Amodiaquine-d10 is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect[1][2][3][4].
|
-
- HY-17589AS
-
-
- HY-17589S1
-
-
- HY-W112166
-
|
|
Others
|
Infection
|
|
(E/Z)-4,4'-Dicyanostilbene is the isomer of 4,4'-Dicyanostilbene (HY-W112166A), and can be used as an experimental control. 4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-17589S
-
-
- HY-17589R
-
|
|
Parasite
Autophagy
SARS-CoV
Toll-like Receptor (TLR)
HIV
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Chloroquine (phosphate) (Standard) is the analytical standard of Chloroquine (phosphate). This product is intended for research and analytical applications. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
|
-
- HY-106005
-
|
|
Parasite
PI4K
|
Infection
|
|
MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kd app=0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent .
|
-
- HY-13832S2
-
|
Atavaquone-d5
|
Isotope-Labeled Compounds
Parasite
Cytochrome P450
Antibiotic
|
Infection
|
|
Atovaquone-d5 is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].
|
-
- HY-13832S3
-
|
cis-Atavaquone-d4
|
Isotope-Labeled Compounds
Parasite
Cytochrome P450
Antibiotic
|
Infection
|
|
cis-Atovaquone-d4 is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14749AS
-
|
|
|
Pyronaridine-d4 (tetraphosphate) is the deuterium labeled Pyronaridine tetraphosphate[1]. Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection[2][3].
|
-
-
- HY-B0094S
-
|
|
|
Artemisinin-d3 is the deuterium labeled Artemisinin. Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].
|
-
-
- HY-B1896S
-
|
|
|
Piperaquine-d6 is the deuterium labeled Piperaquine[1]. Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin[2][3].
|
-
-
- HY-B0803S
-
|
|
|
Lumefantrine-d18 is the deuterium labeled Lumefantrine, which is an antimalarial agent.
|
-
-
- HY-118865S
-
|
|
|
Piperaquine-d6 (tetraphosphate) is the deuterium labeled Piperaquine tetraphosphate. Piperaquine tetraphosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin[1][2].
|
-
-
- HY-B0806S
-
|
|
|
Proguanil-d6 is the deuterium labeled Proguanil, which is a prophylactic antimalarial agent.
|
-
-
- HY-A0130S
-
|
|
|
Sulfalene- 13C6 is the 13C6 labeled Sulfalene. Sulfalene (Sulfametopyrazine) is an antimalarial agent. Sulfalene is also a long-acting sulfonamide antibacterial .
|
-
-
- HY-100662S
-
|
|
|
Didesethyl chloroquine-d4 is the deuterium labeled Didesethyl chloroquine. Didesethyl chloroquine (Bisdesethylchloroquine) is a major metabolite of the antimalarial agent Chloroquine. Didesethyl chloroquine is a potent myocardial depressant[1][2].
|
-
-
- HY-W031727S
-
|
|
|
Hydroxychloroquine-d4-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
-
- HY-W031727S1
-
|
|
|
Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
|
-
-
- HY-B1370S
-
|
|
|
Hydroxychloroquine-d4 (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
|
-
-
- HY-B1322AS
-
|
|
|
Amodiaquine-d10 is the deuterium labeled Amodiaquine. Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect[1][2][3][4].
|
-
-
- HY-17589AS
-
1 Publications Verification
|
|
Chloroquine-d5 is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-17589S1
-
|
|
|
Chloroquine-d4 (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-17589S
-
|
|
|
Chloroquine-d5 (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].
|
-
-
- HY-13832S2
-
|
|
|
Atovaquone-d5 is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].
|
-
-
- HY-13832S3
-
|
|
|
cis-Atovaquone-d4 is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
